Reboxetin in the treatment of depression: Clinical experience of the Austrian observational field trial;Reboxetin in der depressionsbehandlung: Klinische erfahrungen der österreichischen anwendungsbeobachtung

Neuropsychiatrie

Volumn 16, Issue 3-4, 2002, Pages 159-164

  Simhandl, Christian ^a   Valenta, Barbara ^b  

^a Sozial Psychiatrische Abteilung   (Germany)

^b Pharmacia Austria GesmbH   (Austria)

Author keywords

Depression; Efficacy; Post marketing surveillance; Reboxetine; Safety

Indexed keywords

DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MILNACIPRAN; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ARTICLE; AUSTRIA; DEPRESSION; DISABILITY; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; FAMILY LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMARKETING SURVEILLANCE; SIDE EFFECT; WORK DISABILITY;

EID: 0038713292     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ban T.A. et al.: Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological consideration. Hum. Psychopharmacol. 13, 29-39 (1998).
2. Berzewski H., M. Van Moffaert, C.A. Cagiano: Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur. Neuropsychopharmacol. 7 (Suppl. 1), S37-S47 (1997).
3. Dencker S.J.: The need for new and better antidepressants: reboxetine a new option. Acta Psychiatr. Scand. 101 (Suppl. 402), 6-11 (2000).
4. Dubini A. et al.: Do noradrenaline and serotonine differentially affect social motivation and behaviour? Eur. Neuropsychopharmacol. 7 (Suppl.), S49-S56 (1997).
5. Healy D., McMonagle: The enhancement of social functioning as a therapeutic principle in the management of depression. J. Psychopharmacol. 11 (Suppl), S25-S31 (1997).
6. Healy D., Reboxetine: its effects as measured by the social adaptation self-evaluation scale, Acta Psychiatr. Scand. 101 (Suppl. 402), 54-51 (2000).
7. Kasper S.: From symptoms to social functioning: differential effects of anti-depressant therapy. Int. J. Clin. Psychopharmacol. 14 (Suppl. 1), S27-S31 (1999).
8. Massana J. et al.: Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int. J. Clin. Psychopharmacol. 14, 73-80 (1999).
9. Montgomery S.A.: Reboxetine: additional benefits to the depressed patient. J. Psychopharmacol. 11 (Suppl.), S9-S15 (1997).
10. Nutt D.J.: Noradrenaline in depression: half a century of progress. J. Psychopharmacol. 11 (4) (Suppl.), S3 (1997).
11. Riva M, et al.: Effect of reboxetine, a new antidepressant drug on the central noradrenergic system: behavioural and biochemical studies. J. Drug Dev. 1. 243-253 (1989).
12. Sheehan D. V., K. Harnett-Sheehan, B.A. Raj: The measurement of disability. Int. J. Clin. Psychopharmacol. 11 (Suppl. 3), 89-95 (1996).
13. Simhandl Ch., B. Leitner: Praktische Erfahrungen mit Paroxetin in der Depressionsbehandlung. Neuropsychiatrie 12, 110-115 (1998).
14. Simhandl Ch.: Antidepressive Therapie mit Mirtazapin unter Routinebedingungen. Neuropsychiatric 13, 204-211 (1999).
15. Stuppäck C.: Eine Anwendungsbeobachtung mit Milnacipran. Jatros Neurol. Psychiatrie 5, 2-4 (2000).